News
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.
The U.S. Food and Drug Administration has approved Moderna’s (NASDAQ:MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing ...
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...
The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...
The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...
The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results